Physician profile
Russell E Hatley
NPI 1932194974
$1,546.22
in general payments reported to CMS, 2019-2025
24 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $209 · 2021: $158 · 2022: $157 · 2023: $242 · 2024: $331 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $723.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $332.25 | 2019-2025 | Veozah |
| Novo Nordisk INC | $185.84 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Abbvie INC. | $171.50 | 2022-2025 | |
| Glaxosmithkline, LLC. | $124.96 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $101.22 | 2019-2022 | |
| Boston Scientific Corporation | $75.30 | 2019-2023 | Watchman, Watchman Access System |
| Takeda Pharmaceuticals U.S.A., INC. | $67.87 | 2019-2021 | |
| Pfizer INC. | $66.47 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $59.65 | 2019-2021 | |
| Exact Sciences Corporation | $56.09 | 2023-2024 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $51.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $42.53 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $37.47 | 2021-2022 | |
| Genentech USA, INC. | $23.76 | 2020 | |
| Celgene Corporation | $23.01 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $21.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $17.59 | 2023 | Evusheld |
| Amarin Pharma, INC. | $16.84 | 2020 | |
| Mylan Specialty L.P. | $14.34 | 2021 | |
| Esperion Therapeutics, INC. | $12.21 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.38 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.23 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.17 | 2021 | |
| Lilly USA, LLC | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Hatley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.